NFE2L2 and cancer: Recently, Milkovic and colleagues reviewed the controversy around the pharmacological modulation of Nrf2 in relation to cancer therapy, and emphasized the need for a further investigation into inhibitors of Nrf2, which could be a proto-oncogene of cancer patients [234].